Atezolizumab in Japanese Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study

Clinical Lung Cancer

Volumn 19, Issue 4, 2018, Pages e405-e415

  Hida, Toyoaki ^a   Kaji, Reiko ^b   Satouchi, Miyako ^c   Ikeda, Norihiko ^d   Horiike, Atsushi ^e   Nokihara, Hiroshi ^f   Seto, Takashi ^g   Kawakami, Tomohisa ^h   Nakagawa, Shintaro ^h   Kubo, Toshio ⁱ  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c HYOGO CANCER CENTER   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e CANCER CHEMOTHERAPY CENTER   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h CHUGAI PHARMACEUTICAL CO LTD   (Japan)

ⁱ OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Anti PD L1; Cancer immunotherapy; Docetaxel; Japan; TECENTRIQ

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE INHIBITOR; ATEZOLIZUMAB; DOCETAXEL; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CANCER GROWTH; CANCER INFILTRATION; CANCER PATIENT; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL OUTCOME; COLITIS; CONSTIPATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EDEMA; ELECTROCORTICOGRAPHY; ENDOCRINE DISEASE; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENE MUTATION; HAZARD RATIO; HEADACHE; HEPATITIS; HISTOLOGY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFUSION RELATED REACTION; INTENTION TO TREAT ANALYSIS; JAPANESE (PEOPLE); LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL HISTORY; MENINGOENCEPHALITIS; MYALGIA; MYOCARDITIS; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PANCREATITIS; PATIENT HISTORY OF CHEMOTHERAPY; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SENSORY NEUROPATHY; STOMATITIS; TOBACCO USE; TUMOR CELL; ASIAN CONTINENTAL ANCESTRY GROUP; LUNG TUMOR; MIDDLE AGED; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; DOCETAXEL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGRESSION-FREE SURVIVAL; TREATMENT OUTCOME;

EID: 85042905674     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2018.01.004     Document Type: Article

References (25)

1. Cancer Information Service. Projected cancer statistics, 2016. Available at: http://ganjoho.jp/en/public/statistics/short_pred.html Accessed: July 26, 2017.
2. Morgensztern, D., Ng, S.H., Gao, F., Govindan, R., Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5 (2010), 29–33.
3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Non-small cell lung cancer, v2.2018 2017. Available at: https://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf Accessed: December 20, 2017.
4. Wang, F., Mishina, S., Takai, S., et al. Systemic treatment patterns with advanced or recurrent non-small cell lung cancer in Japan: a retrospective hospital administrative database study. Clin Ther 39 (2017), 1146–1160.
5. Japan Society of Oncology. Guideline for clinical practice of lung cancer: II. Non-small cell lung cancer 2016. Available at: http://www.haigan.gr.jp/guideline/2016/1/2/160102060100.html Accessed: July 27, 2017.
6. Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
7. Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
8. Herbst, R.S., Soria, J.C., Kowanetz, M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
9. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
10. Nishio, M., Hida, T., Atagi, S., et al. Multicentre phase II study of nivolumab in Japanese patients with advance or recurrent non-squamous non-small cell lung cancer. ESMO Open, 2, 2016, e000108.
11. Hida, T., Nishio, M., Nogami, N., et al. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Cancer Sci 108 (2017), 1000–1006.
12. McDermott, D.F., Sosman, J.A., Sznol, M., et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34 (2016), 833–842.
13. Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
14. Balar, A.V., Galsky, M.D., Rosenberg, J.E., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389 (2017), 67–76.
15. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
16. Rittmeyer, A., Barlesi, F., Waterkamp, D., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (2017), 255–265.
17. Yano, R., Konno, A., Watanabe, K., et al. Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials. Int J Clin Oncol 18 (2013), 96–104.
18. Noda, K., Nishiwaki, Y., Kawahara, M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2002), 85–91.
19. Lara, P.N. Jr., Natale, R., Crowley, J., et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27 (2009), 2530–2535.
20. Kudoh, S., Kato, H., Nishiwaki, Y., et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177 (2008), 1348–1357.
21. Shi, L., Tang, J., Tong, L., Liu, Z., Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer 83 (2014), 231–239.
22. Yatabe, Y., Kerr, K.M., Utomo, A., et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol 10 (2015), 438–445.
23. Herbst, R.S., Baas, P., Kim, D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
24. + NSCLC: results from the randomized OAK study. Ann Oncol 28:suppl 5 (2017), v460–v466.
25. Wolchok, J.D., Hoos, A., O'Day, S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.